Molecular Docking Study of Anthocyanidin Compounds Against Epidermal Growth Factor Receptor (EGFR) as Anti-Lung Cancer

Riska Prasetiawati; Meilia Suherman; Benny Permana; Rahmawati Rahmawati

doi:10.24198/ijpst.v8i1.29872

Molecular Docking Study of Anthocyanidin Compounds Against Epidermal Growth Factor Receptor (EGFR) as Anti-Lung Cancer

Riska Prasetiawati, Meilia Suherman, Benny Permana, Rahmawati Rahmawati

Abstrak

It is presumed that antiproliferative activity of anthocyanidin has interaction with Epidermal Growth Factor Receptor (EGFR) which has effect on lung cancer cell growth. This study aimed to observe the interaction between anthocyanidin and EGFR and to find out prediction, absorption, distribution activities as well as anthocyanidin toxicity compared to Gefitinib, an EGFR inhibitor. All test compounds were optimized with Autodock Tools®, then molecular docking simulations and predictions of absorption, distribution and toxicity were carried out. Malvidin was stated to meet the Lipinski's Rule of Five, indicating good bioavailability. Result of molecular docking simulation showed that malvidin had better affinity against EGFR than Gefitinib. Molecular docking visualization result showed that malvidin had interaction with amino acid residue such as Met793, Gln791, Leu718, Thr854, Asp855 and Lys745. Absorption and distribution predictions included percentage scores of Human Intestinal Absorption (HIA), human colon adenocarcinoma (Caco-2), and Plasma Protein Binding. Toxicity test revealed that malvidin was mutagenic compound but not carcinogenic one. The findings indicated that malvidin was potential to be an anti lung cancer candidate through EGFR inhibition.

Keywords: Antiproliferative, Anthocyanidin, Epidermal Growth Factor Receptor, Molecular Docking

Teks Lengkap:

PDF

Referensi

Liu TC, Jin X, Wang Y, Wang K.. Role of epidermal growth factor receptor in lung cancer and targeted therapies. Am J Cancer Res 2017;7(2):187-202

Aqil F, Jeyabalan J, Kausar H, Munagala R, Singh IP, Gupta R. Lung cancer inhibitory activity of dietary berries and berry polyphenolics. J Berry Res. 2016;6(2):105–14.

RI PD dan IKK. Situasi Penyakit Kanker [Internet]. Jakarta; 2015. Available from: https://pusdatin.kemkes.go.id/article/ view/15090700004/situasi-penyakitkanker.html

Pucci C, Martinelli C, and Ciofani G. Innovative approaches for cancer treatment: current perspectives and new challenges. Ecancermedicalscience. 2019; 13: 961.

Falzone L, Salomone S, Libra M. Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol. 2018;9(11):1300.

Aqil F, Gupta A, Munagala R, Jeyabalan J, Kausar H, Sharma RJ, et al. Antioxidant and antiproliferative

activities of anthocyanin/ellagitanninenriched extracts from Syzygium cumini L. (Jamun, the Indian Blackberry). Nutr Cancer. 2012;64(3):428–38.

Schirrmacher V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). Int J Oncol. 2019;54(2):407–19.

Lin BW, Gong CC, Song HF, Cui YY. Effects of anthocyanins on the prevention and treatment of cancer. Br J Pharmacol. 2017;174(11):1226–43.

Diaconeasa Z, Leopold L, Rugină D, Ayvaz H, Socaciu C. Antiproliferative and antioxidant properties of anthocyanin rich extracts from blueberry and blackcurrant juice. Int J Mol Sci. 2015;16(2):2352–65.

Zhu SJ, Zhao P, Yang J, Ma R, Yan XE, Yang SY, et al. Structural insights into drug development strategy targeting EGFR T790M/C797S. Oncotarget. 2018;9(17):13652–65.

Nurwidya F, Takahashi F, Takahashi K. Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation. J Nat Sci Biol Med. 2016;7(2):119-123.

Heald R, Bowman KK, Bryan MC, Burdick D, Chan B, Chan E, et al. Correction to Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study. J Med Chem. 2016;59(6):2848–2848.

Kong LL, Ma R, Yao MY, Yan XE, Zhu SJ, Zhao P, et al. Structural pharmacological studies on EGFR T790M/C797S. Biochem Biophys Res Commun. 2017;488(2):266–72.

Yoshikawa S, Kukimoto-Niino M, Parker L, Handa N, Terada T, Fujimoto T, et al. Structural basis for the altered drug sensitivities of non-small cell lung cancerassociated mutants of human epidermal growth factor receptor. Oncogene. 2013;32(1):27–38.

Metro G and Crinò L. Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res. 2012 Mar; 1(1): 5–13.

Agarwal S, Mehrotra R. An overview of Molecular Docking. JSM Chem.

;4(2):1024.

Schneider G. Prediction of Drug-Like Properties. In: Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience; 2000-2013. Available from: https://www.ncbi.nlm.nih.gov/books/ NBK6404/

Gajiwala KS, Feng J, Ferre R, Ryan K, Brodsky O, Weinrich S, et al. Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. Structure. 2013;21(2):209–19.

Nursamsiar, Toding AT, Awaluddin A. Studi In Silico Senyawa Turunan Analog Kalkon dan Pirimidin sebagai Antiinflamasi: Prediksi Absorpsi, Distribusi, dan Toksisitas. Pharmacy. 2016;13(1):92–100.

Shargel L, Yu ABC. Applied Biopharmaceutics and Pharmacokinetics 7th Edition. New York : McGraw Hill, 2016;. 273 p.

Hsu KH, Su BH, Tu YS, Lin OA, and Tseng YJ. Mutagenicity in a Molecule:Identification of Core Structural Features of Mutagenicity Using a Scaffold Analysis. PLoS One. 2016; 11(2).

Andersen OM, Jordheim M. Anthocyanins. Encyclopedia of live science (ELS). 2010;(10). https://doi.

org/10.1002/9780470015902.a0001909. pub2

DOI: https://doi.org/10.24198/ijpst.v8i1.29872